Trial Profile

A Prospective Pragmatic Clinical Trial Of China Early Invasive Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 29 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Exemestane (Primary)
Indications Early breast cancer
Focus Therapeutic Use
Sponsors Pfizer

Most Recent Events

01 Jan 2019 Status changed from recruiting to completed.
03 Dec 2018 Planned End Date changed from 1 Dec 2018 to 28 Nov 2018.
09 Dec 2015 Planned End Date changed from 1 Mar 2019 to 1 Dec 2018 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com